Screener
PBE vs PBUS
Invesco Biotechnology & Genome ETF vs Invesco MSCI USA ETF
Key differences
- PBUS costs 0.54% less per year.
- PBUS is significantly larger than PBE — larger funds tend to be more liquid and less likely to close.
- Over the last 3 years, PBUS has delivered higher annualized returns.
- PBE has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| PBE | PBUS | |
|---|---|---|
| Annual cost (TER) | 0.58% | 0.04% |
| Fund size (AUM) | $247M | $10.7B |
| Since | 2005 | 2017 |
| Dividend yield | 1.09% | 1.03% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +35.8% | +30.6% |
| CAGR 3Y | +10.3% | +23.2% |
| CAGR 5Y | +3.5% | +14.0% |
| Sharpe 3Y | 0.41 | 1.23 |
| Volatility 1Y | 18.63% | 12.22% |
| Max drawdown | -37.84% | -33.15% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to PBE and PBUS
Explore further